Throughout 2025 and into early 2026, healthcare services companies navigated a period of significant policy and macroeconomic volatility, including an evolving trade environment, looming Medicaid budget cuts from the “One Big Beautiful Bill Act”, significantly lower-than-expected Medicare Advantage rate notice and uncertainty around the future of ACA subsidies. Against that backdrop, Lazard fielded this year’s study, which included participation from 192 leaders across many of the largest healthcare services companies as well as small and mid-sized private companies and prominent investment firms.
Read the full article: Lazard Healthcare Services Leaders Study 2026 //
Source: https://www.lazard.com/research-insights/lazard-healthcare-services-leaders-study-2026/